Assessment Status | Rapid Review Complete |
HTA ID | 23001 |
Drug | Difelikefalin |
Brand | Kapruvia® |
Indication | For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. |
Assessment Process | |
Rapid review commissioned | 09/01/2023 |
Rapid review completed | 02/02/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of difelikefalin compared with the current standard of care. |